Euroeyes International Eye Clinic : FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILISING ACTIONS AND END OF STABILISATION PERIOD

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 30 September 2019 (the "Prospectus ") issued by EuroEyes International Eye Clinic Limited (the "Company").

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the U.S. Securities Act. The securities may not be offered, pledged, transferred, delivered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities by the Company in the United States.

EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,

STABILISING ACTIONS AND END OF STABILISATION PERIOD

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by BOCI Asia Limited ("BOCI") (on behalf of the International Underwriters) on

7 November 2019 in respect of 11,900,000 additional Shares (the "Over-allotmentShares"), representing 15% of the Offer Shares initially available under the Global Offering. No further exercise of the Over-allotment Option will be carried out by BOCI. The Over-allotment Shares will be issued and allotted at HK$7.50 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on Thursday, 7 November 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of stabilising actions undertaken by the Stabilising Manager during the stabilisation period is set out in this announcement.

1

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by the Sole Global Coordinator (on behalf of the International Underwriters) on 7 November 2019 in respect of 11,900,000 additional Shares, representing 15% of the Offer Shares initially available under the Global Offering. No further exercise of the Over-allotment Option will be carried out by the Sole Global Coordinator.

The Over-allotment Shares will be used to facilitate the return in full the borrowed Shares borrowed by the Stabilising Manager from Dr. Jørn Slot Jørgensen under the Stock Borrowing Agreement, which were used to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted at HK$7.50 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-allotment Shares have already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at or around 9:00 a.m. on 14 November 2019.

Shareholding Structure of the Company upon the full exercise of the Over-allotment Option

The shareholding structure of the Company immediately before and after the issue of the Over- allotment Shares is as follows:

Shareholders

Dr. Jørgensen (Note 1)

ØJENKROGEN ApS (Note 3)

Ms. Antonie Neuhann (Note 4)

Mr. Jannik Jørgensen (Note 1)

Dr. Lerche (Note 1)

Dr. Markus Braun (Note 1)

Mr. Marcus Huascar Bracklo (Note 5) Dr. Susanne Jørgensen (Note 6)

Dr. Claudia Lerche (Note 7)

Immediately before	Immediately after
the issue of	the issue of
the Over-allotment Shares	the Over-allotment Shares
	Approximate		Approximate
	percentage of		percentage of
	the Company's		the Company's
Number of	issued share	Number of	issued share
Shares	capital	Shares	capital
167,678,000 (Note 2)	52.84%	167,678,000	50.93%
14,805,000	4.67%	14,805,000	4.50%
6,685,000	2.11%	6,685,000	2.03%
5,171,400	1.63%	5,171,400	1.57%
3,087,000	0.97%	3,087,000	0.94%
238,000	0.07%	238,000	0.07%
238,000	0.07%	238,000	0.07%
41,500	0.01%	41,500	0.01%
14,000	0.01%	14,000	0.004%
2

	Immediately before	Immediately after
	the issue of	the issue of
	the Over-allotment Shares	the Over-allotment Shares
			Approximate			Approximate
			percentage of			percentage of
			the Company's			the Company's
Shareholders	Number of	issued share	Number of		issued share
Shares	capital	Shares		capital
Public Shareholders:
Ling Rui International	23,107,000		7.28%	23,107,000	7.02%
Mr. Hassel	6,685,000		2.11%		6,685,000	2.03%
Professor Knorz	2,940,000		0.93%		2,940,000	0.89%
Ms. Yan Wang	714,000		0.22%		714,000	0.22%
Mr. Keith Nicholas McKay	476,000		0.15%		476,000	0.14%
Other Pre-IPO Investors (Note 8)	6,188,000		1.95%		6,188,000	1.88%
Other public Shareholders	79,266,100		24.98%		91,166,100	27.69%
Sub-total of public Shareholders	119,376,100		37.62%	131,276,100	39.87%
Total	317,334,000		100.00%	329,234,000	100.00%

Note:

1. Each of Dr. Jørgensen, Mr. Jannik Jørgensen, Dr. Lerche and Dr. Markus Braun is an executive Director.
2. These Shares include the 11,900,000 Shares borrowed by the Stabilising Manager pursuant to the Stock Borrowing Agreement.
3. ØJENKROGEN ApS, a company incorporated in Denmark with limited liability, is wholly-owned by Dr. Boberg-Ans, who is a director and chief executive officer of EUROEYES ApS, a wholly-owned subsidiary of the Company.
4. Ms. Antonie Neuhann is the spouse of Professor Neuhann, an executive Director.
5. Mr. Marcus Huascar Bracklo is a non-executive Director.
6. Dr. Susanne Jørgensen is the spouse of Dr. Jørgensen, an executive Director.
7. Dr. Claudia Lerche is the spouse of Dr. Lerche, an executive Director.
8. Other Pre-IPO Investors refer to (i) Mr. Thomas Gottschalk, (ii) Dr. Hans-Göran Gustaf Helgason, (iii) Ms. Thea Gottschalk, (iv) Dr. Mathias Fleischer, (v) Dr. Frank Schreyger, (vi) Mr. Shu Pai Li, (vii) Mr. Lars Meier, (viii) Ms. Lam Na Linda Li and (ix) Ms. Xia Huang.

The additional net proceeds of approximately HK$86.6 million, after deducting the underwriting fees and commissions, from the issue of the Over-allotment Shares will be applied on a pro-rata basis in accordance with those stated in the section headed "Future Plans and Use of Proceeds - Use of Proceeds" in the Prospectus.

3

STABILISING ACTIONS AND END OF STABILISATION PERIOD

The Company announces that, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the stabilisation period in connection with the Global Offering ended on Thursday, 7 November 2019, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilisation actions undertaken by the Stabilising Manager, its affiliates or any person acting for it during the stabilisation period involved:

1. over-allocationsof an aggregate of 11,900,000 Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
2. borrowing of an aggregate of 11,900,000 Shares by BOCI, the Stabilising Manager, from Dr. Jørn Slot Jørgensen pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering;
3. the full exercise of the Over-allotment Option by BOCI, on behalf of the International Underwriters, on 7 November 2019, in respect of an aggregate of 11,900,000 Shares, representing 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Share, to cover the over-allocations in the International Offering.

The Shares borrowed from Dr. Jørn Slot Jørgensen pursuant to the Stock Borrowing Agreement will be returned to Dr. Jørn Slot Jørgensen in accordance with the terms of the Stock Borrowing Agreement.

4

PUBLIC FLOAT

Immediately after the full exercise of the Over-allotment Option, the Company continues to comply with the public float requirements under Rules 8.08(1)(a) of the Listing Rules.

Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments. Accordingly, figures shown in certain tables may not be an arithmetic aggregate of the figures preceding them.

By order of the Board

EuroEyes International Eye Clinic Limited

Dr. Jørn Slot Jørgensen

Chairman and Executive Director

Hong Kong, 8 November 2019

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Prof. Dr. Thomas Friedrich Wilhelm Neuhann and Mr. Jannik Jonas Slot Jørgensen as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Mr. Zhengzheng Hu and Mr. Philip Duncan Wright as independent non-executive Directors.

5